MabSelect PrismA has been improved with an optimised high-flow agarose base matrix and a genetically engineered protein A-derived ligand, allowing future demands in mAb processing to be met.

• Enhanced dynamic binding capacity allows high mass throughput of processed mAb per resin volume unit
• Excellent alkaline stability enables efficient cleaning and sanitisation using 0.5 - 1.0 M NaOH for improved process economy, bioburden control and robustness
• Covered by a comprehensive security of supply program, including dual sources of the agarose base matrix and protein A ligand